Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

4.000 +0.540 (+15.61%)
Streaming Delayed Price Updated: 10:16 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Lisata Therapeutics ↗
 
Via Benzinga
News headline image
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024 ↗
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
News headline image
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy ↗
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
Via Benzinga
News headline image
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results 
Via News Direct
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the... 
Via TheNewswire.com
News headline image
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024 ↗
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.